{
  "pmcid": "3812363",
  "sha256": "989204302ba92ee1fdeb353a685777776e60a6dff749c4cf746ee1523d4dc7c7",
  "timestamp_utc": "2025-11-09T22:38:59.925318+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 14.184548658172947,
    "reading_ease": 16.101865004066156,
    "word_count": 217
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Dendritic Cell and Poxvector Vaccines in Colorectal Cancer"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "In this randomised controlled trial, 74 patients disease-free after CRC metastasectomy and perioperative chemotherapy were randomised"
      },
      "Participants": {
        "score": 1,
        "evidence": "patients disease-free after CRC metastasectomy and perioperative chemotherapy"
      },
      "Intervention": {
        "score": 2,
        "evidence": "randomised to receive either autologous DCs modified with PANVAC (DC/PANVAC) or PANVAC with granulocyte-macrophage colony-stimulating factor (GM-CSF)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluates whether vaccines based on dendritic cells (DCs) and poxvectors encoding carcinoembryonic antigen (CEA) and MUC1 (PANVAC) improve survival in patients with resected CRC metastases."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was recurrence-free survival at 2 years."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Blinding was not specified."
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "74 patients disease-free after CRC metastasectomy and perioperative chemotherapy were randomised"
      },
      "Number_Analysed": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Result_Outcome": {
        "score": 2,
        "evidence": "At 2 years, recurrence-free survival was 47% for DC/PANVAC and 55% for PANVAC/GM-CSF (Ï‡2 P = 0.48)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT00103142."
      },
      "Funding": {
        "score": 0,
        "evidence": "Funding: [source of funding]."
      }
    },
    "total_score": 14,
    "max_score": 25
  }
}